Rex Hoffman, M.D., MBA, says physician shortages and burnout are the most underestimated pressures on health system.
News|Articles|January 1, 2026
Top 5 dermatology articles of 2025
Author(s)MHE Staff
Listen
0:00 / 0:00
Key Takeaways
- Semaglutide, a GLP-1 drug, is potentially linked to allodynia, a rare painful skin sensitivity condition, according to recent research.
- Climate change and air pollution are increasingly associated with worsening atopic dermatitis, affecting up to 15% of the global population.
New studies from the year revealed connections between medications, environmental factors and innovative treatments for skin conditions including vitiligo and atopic dermatitis.
Advertisement
- Study Links Semaglutide to Rare Skin Pain Condition
New research published in the American Journal of Health-System Pharmacy suggests a possible link between the GLP-1 drug semaglutide and allodynia, a painful skin sensitivity.Read more - Higher Air Pollution and Extreme Weather Linked to Adult Atopic Dermatitis
Climate change and air pollution are growing threats to public health, and new research suggests they may also worsen atopic dermatitis (AD), the most common chronic inflammatory skin condition, affecting up to 15% of people worldwide.Read more
- Regenerative Medicine Offers Positive Results for Treating Vitiligo
Regenerative medicine focuses on repairing damaged skin and bringing back melanocytes, the cells that give skin its color.Read more - Combined Oral and Phototherapy Treatments Show Promise in Treating Severe Vitiligo
In a phase 2 clinical trial, researchers examined baricitinib and NB-UVB in adults with severe vitiligo in the dermatology departments at 4 hospitals in France between July 2021 and April 2023.Read more - Opzelura Topical Cream Drives Incyte's Record Growth in 2024 with 50% Revenue Surge
Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S. that helps restore skin color for this condition. It’s also approved to treat mild to moderate atopic dermatitis in patients 12 and older who are not immunocompromised.Read more
Advertisement
Related to this article
Rex Hoffman, M.D., MBA, of Providence Holy Cross walks through a CMO’s day in a hospital that often runs 85% to 100% full, from safety huddles to discharges.
On average, caregivers want to see their children with ADHD fall asleep 30 minutes faster, but the best sleep treatments average approximately 20 minutes, a new survey study found.
Research findings presented at CHEST meeting show COPD hospital readmission drops with discharge checklists and navigation. Other research suggests targeting readmission prevention efforts on patents discharged to post-acute facilities.
As the pharmacist pipeline tightens, leaders from UC Davis Health, UCSF Health, and Sutter Health say financial sustainability now depends as much on capacity as on cost.
GLP-1 use in adults 65 and older with MASLD was linked to a 45% lower risk of death, and a 28% lower risk of hepatic decompensation, a new Houston Methodist Research Institute study shows.
New data from Sutter Health suggest the real gap in GLP-1 access is physician awareness, not insurance coverage — and fixing it closed outcome disparities across every racial and ethnic group.
Research findings presented at the CHEST meeting show that false positives may make patients more adherent to screening. Qualitative research shows that patients want more explanation and results communicated verbally.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
GLP-1 therapy tied to lower mortality and liver decompensation in older adults with MASLD
2
Kaiser’s formulary chief makes his case for a ‘total value’ model on biologics | HSES 2026
3
Health-system pharmacy leaders are being asked to solve a margin problem and it is costing hospitals | HSES 2026
4
The GLP-1 access gap in type 2 diabetes isn’t coverage — it’s physician awareness | HSES 2026
5